2.85 on the TAI. This SniperIQ fundamentals page covers Sinphar Pharmaceutical's valuation (P/E 18.8x, P/B 1.6x), profitability (net margin 9.6%), revenue (NT.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT$6.2B
P/E (TTM)18.8x
Net Margin9.6%
Revenue (FY25)NT
.4B

Full research coverage

Frequently Asked Questions

What is Sinphar Pharmaceutical's market cap?

Sinphar Pharmaceutical (1734) has a market capitalization of approximately NT$6.2B, trading at NT

2.85 on the TAI. Market cap moves with the live share price.

What is Sinphar Pharmaceutical's P/E ratio?

Sinphar Pharmaceutical's trailing twelve-month P/E ratio is 18.8x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Sinphar Pharmaceutical?

Sinphar Pharmaceutical runs a net profit margin of 9.6%, a gross margin of 42.9%, and an operating margin of 11.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Sinphar Pharmaceutical generate?

Sinphar Pharmaceutical reported revenue of NT

.4B for fiscal year 2025, with net income of NT66M and earnings per share (EPS) of 1.92. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Sinphar Pharmaceutical pay a dividend?

Sinphar Pharmaceutical offers a trailing dividend yield of about 2.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Sinphar Pharmaceutical financially healthy?

Sinphar Pharmaceutical carries a debt-to-equity ratio of 0.48x and a current ratio of 2.37x, with a market beta of 0.11. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Sinphar Pharmaceutical a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sinphar Pharmaceutical (1734) the key facts are: market cap NT$6.2B, P/E 18.8x, revenue NT

.4B, 52-week range 29.66667-34.55. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Sinphar Pharmaceutical's full fundamentals live

Get Sinphar Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.